These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 21350317)

  • 21. [Effect of calcitriol on secondary hyperparathyroidism].
    Xu H; Zhang J; Cheng X; Zhou Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):920-4. PubMed ID: 24071691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D
    Pandey R; Zella JB; Zhu JG; Plum LA; Clagett-Dame M; Blaser WJ; Bedale W; DeLuca HF; Coyne DW
    Drugs R D; 2017 Dec; 17(4):597-605. PubMed ID: 28905271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
    Lomonte C; Martino R; Selvaggiolo M; Bona RM; Cazzato F; Milano R; Chiarulli G; Basile C
    J Nephrol; 2003; 16(5):716-20. PubMed ID: 14733419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.
    Quarles LD; Yohay DA; Carroll BA; Spritzer CE; Minda SA; Bartholomay D; Lobaugh BA
    Kidney Int; 1994 Jun; 45(6):1710-21. PubMed ID: 7933819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous calcitriol versus paricalcitol in haemodialysis patients with severe secondary hyperparathyroidism.
    Abdul Gafor AH; Saidin R; Loo CY; Mohd R; Zainudin S; Shah SA; Norella KC
    Nephrology (Carlton); 2009 Aug; 14(5):488-92. PubMed ID: 19298641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
    Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
    Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of cinacalcet combined with low-dose calcitriol on clinical outcome and bone metabolism in patients with severe secondary hyperparathyroidism].
    Yuan F; Chen X; Wang C; Zhou A; Liu H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 42(10):1169-1173. PubMed ID: 29093248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.
    Bacchini G; Fabrizi F; Pontoriero G; Marcelli D; Di Filippo S; Locatelli F
    Nephron; 1997; 77(3):267-72. PubMed ID: 9375818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
    Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
    Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulse oral calcitriol to treat hyperparathyroidism in 43 CAPD patients.
    Juergensen P; Santacroce S; Mooraki A; Cooper K; Finkelstein FO; Kliger AS
    Adv Perit Dial; 1994; 10():259-60. PubMed ID: 7999840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol.
    Gallieni M; Brancaccio D; Padovese P; Rolla D; Bedani P; Colantonio G; Bronzieri C; Bagni B; Tarolo G
    Kidney Int; 1992 Nov; 42(5):1191-8. PubMed ID: 1453603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism.
    Oyama Y; Kazama JJ; Omori K; Higuchi N; Kameda S; Yamamoto S; Ito Y; Maruyama H; Narita I; Gejyo F
    Clin Exp Nephrol; 2005 Jun; 9(2):142-7. PubMed ID: 15980949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.
    Vulpio C; Maresca G; Distasio E; Cacaci S; Panocchia N; Luciani G; Bossola M
    Hemodial Int; 2011 Jan; 15(1):69-78. PubMed ID: 21223484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
    Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK
    Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients.
    Lin CL; Hung CC; Yang CT; Huang CC
    Ren Fail; 2004 May; 26(3):289-95. PubMed ID: 15354979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of serum 1,84 iPTH after high dose of calcitriol in uremic patients.
    Seidel A; Herrmann P; Klaus G; Mehls O; Schmidt-Gayk H; Ritz E
    Clin Nephrol; 1993 Apr; 39(4):210-3. PubMed ID: 8491051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous 1,25(OH)2D therapy increases the intact parathyroid hormone secretion set point in hemodialyzed patients.
    Brossard JH; Roy L; Lepage R; Gascon-Barré M; D'Amour P
    Miner Electrolyte Metab; 1997; 23(1):25-32. PubMed ID: 9058366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
    Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
    Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.